To determine whether Dynamin inhibitors exhibited subtype-specific efficacy in human T-ALL, we treated patient-derived ETP-ALL and mature T-ALL xenografts21,55 with Dynole 34-2 for an hour prior to in vitro stimulation with growth factors. The gene discussed is DNM1; the disease is acute lymphoblastic leukemia.